Business
MEI Pharma Reports Third Quarter Fiscal Year 2025 Cash Position
Evaluation of Strategic Alternatives is Ongoing MEI Pharma, Inc. (Nasdaq: MEIP) (the ...
About this update from Lithos Group Ltd
[{"type":"text","content":"MEI Pharma Reports Third Quarter Fiscal Year 2025 Cash Position\n\n\n .bwalignc { text-align: center; list-style-position: inside }\n.bwalignl { text-align: left }\n.bwalignr { text-align: right; list-style-position: inside }\n.bwblockalignl { margin-left: 0px; margin-right: auto }\n.bwcellpmargin { margin-bottom: 0px; margin-top: 0px }\n.bwdoublebottom { border-bottom: double black 2.25pt }\n.bwpadb3 { padding-bottom: 4px }\n.bwpadb4 { padding-bottom: 5px }\n.bwpadl0 { padding-left: 0px }\n.bwpadl3 { padding-left: 15px }\n.bwpadl6 { padding-left: 30px }\n.bwpadr0 { padding-right: 0px }\n.bwrowaltcolor0 { background-color: #cceeff }\n.bwsinglebottom { border-bottom: solid black 1pt }\n.bwtablemarginb { margin-bottom: 10px }\n.bwuline { text-decoration: underline }\n.bwvertalignb { vertical-align: bottom }\n.bwvertalignt { vertical-align: top }\n.bwwidth1 { width: 1% }\n.bwwidth10 { width: 10% }\n.bwwidth100 { width: 100% }\n.bwwidth49 { width: 49% }\n.bwwidth75 { width: 75% }\n \n\n\n\n\n Evaluation of Strategic Alternatives is Ongoing\n \n\n\n\n\n MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today reported results for its third quarter ended March 31, 2025.\n \n\n As previously announced in July 2024, the Company is continuing its review and evaluation of potential strategic alternatives. As part of this assessment, the Company is considering options such as out-licensing opportunities for existing programs and merger and acquisition opportunities, with the goal of maximizing the value of its assets for its stockholders. Oppenheimer & Co., Inc. is serving as the Company’s exclusive financial advisor in this process.\n \n\n Through the third quarter of fiscal year 2025, the Company’s cash preservation efforts continue and include a reduction-in-force progressing in stages as the Company’s operational and strategic direction evolves.\n \n\n There can be no assurance the exploration of strategic alternatives will result in any agreements or transactions, or, if completed, any agreements or transactions will be successful or on attractive terms. The Company does not expect to disclose developments with respect to this process unless or until the evaluation of strategic alternatives has been completed or the Board of Directors has concluded disclosure is appropriate or legally required.\n \n...